top of page

Allergan and AstraZeneca team up to develop ATM-AVI

Allergan and AstraZeneca are to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. With ATM-AVI they present a new treatment option for patients with MBL-producing pathogens.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page